The Business of Biofabrication

EpiBone, Inc., a regenerative medicine company specializing in skeletal reconstruction, has completed a convertible note funding round led by Kendall Capital Partners, with participation from LifeSpan Vision Ventures, EMV Capital plc, and other strategic investors. The specific amount raised in this round has not been disclosed. However, prior to this funding, EpiBone had secured approximately $44.3 million over eight rounds from 26 investors.

The newly acquired capital will support EpiBone’s ongoing pipeline development and facilitate the expansion of its clinical trials into international markets, including Thailand and the United Arab Emirates, both recognized as emerging hubs for medical tourism.

EpiBone’s proprietary technology utilizes autologous and allogeneic stem cells, 3D bioprinting, and bioreactor systems to create personalized skeletal solutions. This approach aims to improve outcomes for bone and osteochondral reconstruction, offering alternatives to traditional musculoskeletal treatments by integrating seamlessly into patients’ bodies.

The consortium of investors acknowledges the global potential of EpiBone’s innovations, emphasizing the importance of commercialization strategies that address international markets from the outset. This investment aligns with broader trends in regenerative medicine, where personalized therapies and advanced technologies are transforming healthcare.

With the additional funding, EpiBone is positioned to advance clinical trials, further its research and development initiatives, and establish a stronger presence in international markets.

How the Technology Works

EpiBone’s technology integrates biological and engineering methods to develop regenerative solutions for skeletal reconstruction. The process uses stem cells, either autologous (sourced from the patient) or allogeneic (from donors), which are applied to custom molded bioreactor to the target tissue’s dimensions. These cells are are then incubated withing physiological conditions, fostering cell growth and tissue development. The resulting constructs are intended to integrate with the patient’s existing anatomy, providing a personalized approach to bone and osteochondral repair. This method aims to address challenges associated with traditional implants, that don’t grow or integrate with the patient.

Technology workflow taken below from Epibone’s website.

About EpiBone

EpiBone, Inc. is a privately held company at the intersection of biology and engineering, focusing on creating living solutions for skeletal reconstruction. The company’s mission is to transform musculoskeletal care through innovation. For more information, visit epibone.com.